|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sodium-glucose co-transporter (SGLT)-2 inhibitors have been shown to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in patients with type 2 diabetes mellitus (DM) and high cardiovascular risk in two large clinical outcome trials: empagliflozin in EMPA-REG OUTCOME and canagliflozin in CANVAS.
|
31747132 |
2020 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to explore potential mediators of the effects of canagliflozin on heart failure in the CANVAS Program (CANagliflozin cardioVascular Assessment Study; NCT01032629 and CANagliflozin cardioVascular Assessment Study-Renal; NCT01989754).
|
31676303 |
2020 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some studies on glucagon-like peptide-1 receptor agonists (liraglutide: LEADER trial; semaglutide: SUSTAIN-6 trial) found significant benefits for MACE, while treatment with sodium-glucose co-transporter-2 inhibitors (empagliflozin: EMPA-REG OUTCOME trial; canagliflozin: CANVAS trial) also significantly reduced MACE and reduced hospitalization for heart failure.
|
30091169 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PMPY costs avoided for heart failure were $2.72 for CANVAS and $1.32 for EMPA-REG.
|
30575426 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three CVOTs of various SGLT-2i (EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58) enrolled markedly different patient populations in terms of ASCVD risk, but have demonstrated robust and consistent benefits in reduction of hospitalization for HF.
|
31081589 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
For major cardiovascular events (MACE), there is no class effect for SGLT-2 inhibitors, as the 7% reduction of MACE risk observed with dapagliflozin in the DECLARE trial was not significant; on the other hand, a class effect is evident for both heart failure and diabetic kidney disease, as in all four trials so far completed (EMPAREG-OUTCOME, CANVAS, DECLARE, CREDENCE) the risk of hospitalization for heart failure and progression of diabetic kidney disease was significantly reduced by all SGLT-2 inhibitors.
|
31337395 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The three trials with sodium glucose co-transporter-2 inhibitors (SGLT-2i) (EMPA-REG OUTCOME with empagliflozin, CANVAS with canagliflozin and DECLARE with dapagliflozin) all revealed a robust and significant reduction in the hazard ratios of hospitalization for HF, from 27% to 35%, which remained consistent, significant and of similar magnitude regardless of the presence of a history of HF or established atherosclerotic cardiovascular disease.
|
30609236 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the CANVAS Program trials using canagliflozin, the rates of the 3-point MACE endpoint, the risk of heart failure and the renal composite endpoint were also reduced, albeit with an increased risk of lower extremity amputation and fracture.
|
29735306 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
LEADER, SUSTAIN-6, EMPA-REG OUTCOME, and CANVAS showed potential beneficial results, while the SAVOR-TIMI trial had an increased rate of hospitalization for heart failure.
|
28894748 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CANVAS trial (Canagliflozin Cardiovascular Assessment Study) subsequently reported a reduction in 3-point major adverse cardiovascular events and HF hospitalization risk.
|
29061576 |
2017 |